share_log

B of A Securities Downgrades Achilles Therapeutics to Underperform, Lowers Price Target to $0.5

Benzinga ·  Dec 14, 2023 07:18

B of A Securities analyst Tazeen Ahmad downgrades Achilles Therapeutics (NASDAQ:ACHL) from Buy to Underperform and lowers the price target from $7 to $0.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment